Regeneron will continue to solely commercialize Evkeeza in the United States. Additionally, Regeneron has granted Ultragenyx an exclusive option to negotiate a separate agreement to collaborate on the development and commercialization of an investigational antibody outside of the United States. The antibody is currently in phase II/III development for the treatment of the ultra-rare disease fibrodysplasia ossificans progressiva (FOP) under terms to be agreed upon by both companies. Regeneron's shares have gained 20% in the past year against the industry 's decline of 31%. Image Source: Zacks Investment Research Regeneron's performance has been outstanding in 2021. Strong demand for Eylea and Dupixent maintained momentum for the company. Incremental contribution from REGEN-COV has boosted the top line significantly.